June 25, 2015 / 3:56 PM / 4 years ago

Bristol-Myers to stop new antiviral drug research

(Reuters) - Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs.

Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision. The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.

The compound is already approved in the European Union to treat the same condition under the brand name Daklinza.

The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.

Bristol-Myers’ stock was up marginally at $67.47 on the New York Stock Exchange.

Reporting by Anjali Rao Koppala in Bengaluru; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below